Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...
Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...
Scientists in the polo-obsessed nation have produced world's first genetically edited horses, designed to outrun champion ...
The next phase of Kilroy's big Oyster Point project is seeing interest from tech and financial services as well as biotech, long the dominant industry in South San Francisco.
Comedian and actor Kheiron unveils his first play, Alba et Sadaf, an intriguing and daring creation. Now playing at the Théâtre des Mathurins, the play tells the true stories of two women living ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback